About 3-hydroxyisobutyrate dehydrogenase, mitochondrial
3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH) is a protein
from Homo sapiens identified by UniProt accession
P31937, 336 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | 3-hydroxyisobutyrate dehydrogenase, mitochondrial |
|---|
| UniProt accession | P31937 |
|---|
| Gene | HIBADH |
|---|
| Organism | Homo sapiens |
|---|
| Length | 336 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- nephrolithiasis · score 0.41
- heel bone mineral density · score 0.38
- risk-taking behaviour · score 0.37
- prostate carcinoma · score 0.35
- body fat percentage · score 0.32
- urolithiasis · score 0.30
- cardiovascular disease · score 0.30
- alcohol consumption measurement · score 0.29
- lower urinary tract calculus · score 0.29
- Inguinal hernia · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P31937-F1 | alphafold | PREDICTED | 90.65 | — |
Amino-acid sequence (336 residues)
MAASLRLLGA ASGLRYWSRR LRPAAGSFAA VCSRSVASKT PVGFIGLGNM GNPMAKNLMK HGYPLIIYDV FPDACKEFQD AGEQVVSSPA DVAEKADRII TMLPTSINAI EAYSGANGIL KKVKKGSLLI DSSTIDPAVS KELAKEVEKM GAVFMDAPVS GGVGAARSGN LTFMVGGVED EFAAAQELLG CMGSNVVYCG AVGTGQAAKI CNNMLLAISM IGTAEAMNLG IRLGLDPKLL AKILNMSSGR CWSSDTYNPV PGVMDGVPSA NNYQGGFGTT LMAKDLGLAQ DSATSTKSPI LLGSLAHQIY RMMCAKGYSK KDFSSVFQFL REEETF
Explore 3-hydroxyisobutyrate dehydrogenase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets